Feasibility Study: Evaluation of the Ulthera® System for Treatment of the Décolleté - Full Text View

Purpose

Up to 20 subjects will be enrolled. Subjects will receive treatment of the décolleté using the Ulthera® System. Subjects will be return for follow-up visits at 90 and 180 days post-treatment. The study will evaluate the effectiveness of the Ulthera® System to lift and tighten the skin of the décolleté region.

Condition	Intervention
Skin Laxity of the décolleté	Device: Ulthera® System


Study Type:	Interventional
Study Design:	Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Feasibility Study: Evaluation of the Ulthera® System for Lifting and Tightening of the Décolleté

Resource links provided by NLM:

Genetics Home Reference related topics: cutis laxa

Genetic and Rare Diseases Information Center resources: Cutis Laxa

U.S. FDA Resources

Further study details as provided by Ulthera, Inc:

Primary Outcome Measures:

Improvement in overall lifting and tightening of skin [ Time Frame: 90 days post-treatment ] [ Designated as safety issue: No ]
Lifting and tightening of décolleté skin as determined by a masked, qualitative assessment of photographs at 90 days posttreatment compared to baseline.

Secondary Outcome Measures:

Skin Laxity of the Décolleté [ Time Frame: 90 and 180 days post-treatment ] [ Designated as safety issue: No ]
The amount of skin laxity will be assessed using the Fabi/Bolton 5-Point Chest Wrinkle Scale. Skin laxity will be assessed at each follow-up visit compared to baseline.
Bilateral chest measurements [ Time Frame: 90 and 180 days post-treatment ] [ Designated as safety issue: No ]
Measurements from mid-clavicle to nipple obtained at each follow-up visit compared to baseline to assess for lifting and tightening of skin.
Overall aesthetic improvement [ Time Frame: 90 and 180 days post-treatment ] [ Designated as safety issue: No ]
Based on Global Aesthetic Improvement Scale (GAIS) scores.
Patient satisfaction [ Time Frame: 90 and 180 days post-treatment ] [ Designated as safety issue: No ]
Subject-completed questionnaire.


Enrollment:	24
Study Start Date:	June 2011
Study Completion Date:	May 2012
Primary Completion Date:	January 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Ultherapy™ treatment on the décolleté All enrolled subjects will receive the study treatment.	Device: Ulthera® System Focused ultrasound energy delivered below the surface of the skin. Other Name: Ultherapy™ treatment

Detailed Description:

This is a prospective, single-center study. Baseline Fabi/Bolton 5-Point Chest Wrinkle scale scores and chest measurements will be assessed prior to study treatment. Study images will be obtained pre-treatment, immediate post-treatment, and at each follow-up visit.

Eligibility


Ages Eligible for Study:	35 Years to 60 Years (Adult)
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Female, aged 35 to 60 years.
Subject in good health.
Moderate to severe (grade of ≥3 on Fabi/Bolton scale) skin laxity on the décolleté.
Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period.
Willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study.

Exclusion Criteria:

Presence of an active systemic or local skin disease that may affect wound healing.
Scarring in areas to be treated.
Tattoos in the areas to be treated.
Patients with ports or defibrillators.
Breast size >400cc each as measured by water displacement method.
History of breast reduction surgery.
Any open wounds or lesions in the area.
Active and severe inflammatory acne in the region to be treated.
Patients who have a history with keloid formation or hypertropic scarring

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01485107

Locations


United States, California
Goldman, Butterwick, Fitzpatrick & Groff of Dermatology Cosmetic Laser
San Diego, California, United States, 92121

Sponsors and Collaborators

Ulthera, Inc

Investigators


Principal Investigator:	Michael Goldman, MD	Goldman, Butterwick, Fitzpatrick & Groff of Dermatology Cosmetic Laser

More Information


Responsible Party:	Ulthera, Inc
ClinicalTrials.gov Identifier:	NCT01485107 History of Changes
Other Study ID Numbers:	ULT-105
Study First Received:	December 1, 2011
Last Updated:	June 27, 2013
Health Authority:	United States: Institutional Review Board

Keywords provided by Ulthera, Inc:


Ulthera® System Ultherapy™ treatment Ulthera, Inc. Ultrasound treatment for skin tightening

Additional relevant MeSH terms:


Cutis Laxa Skin Diseases, Genetic Genetic Diseases, Inborn Connective Tissue Diseases Skin Diseases

ClinicalTrials.gov processed this record on September 23, 2016